Evidence map›Paper›PMID 42006206›Full record

ArticleKidney international reports2026

Enteric Budesonide Treatment in IgA Nephropathy.

Sanjeev Gulati, Arpita Roy Chaudhary, Sanshriti Chauhan, Karan Saraf, Dinesh Khullar, Sanjiv Jasuja, Vinay Rathore, Hari Shankar Meshram, Brad Rovin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Sanjeev GulatiDepartment of Nephrology & Kidney Transplant, Fortis Flt. Lt. Rajan Dhall Hospital, Fortis Group of Hospitals, Vasant Kunj, New Delhi, India.
Arpita Roy ChaudharyDepartment of Nephrology, Institute of Post Graduate Medical Education and Research and SSKM Hospital, Kolkata, West Bengal, India.
Sanshriti ChauhanDepartment of Nephrology & Kidney Transplant, Fortis Flt. Lt. Rajan Dhall Hospital, Fortis Group of Hospitals, Vasant Kunj, New Delhi, India.
Karan SarafDepartment of Nephrology, Apollo Excelcare, Guwahati, Assam, India.
Dinesh KhullarDepartment of Nephrology, Max Super Speciality Hospital, Saket, New Delhi, India.
Sanjiv JasujaDepartment of Nephrology, Indraprastha Appollo Hospital, New Delhi, India.
Vinay RathoreDepartment of Nephrology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Hari Shankar MeshramDepartment of Nephrology, Institute of Liver and Biliary Sciences, Vasant Kunj, New Delhi, India.
Brad RovinDivision of Nephrology, Department of Internal Medicine, Ohio State University, Columbus, Ohio, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Targeted release formulation (TRF)-budesonide was the first drug approved by regulatory authorities for the management of IgA nephropathy (IgAN) but is not available in many countries. Enteric coated (EC)-budesonide is widely available, but there is a paucity of data in IgAN. Methods: This study was a prospective, single arm, multicenter ( Results: The mean age of the cohort was 36.1 ± 11.0 years with 97 males (57.1%). At 9 months ( Conclusion: In this prospective multicenter, single arm study of EC-budesonide in IgAN, the safety, proteinuria reduction, and eGFR stabilization were encouraging. The drug has promising efficacy in regions where other approved drugs are unavailable.

Indexed as

end- stage kidney diseaseIgA nephropathyinfectionoral budesonideproteinuria

Identifiers

PMID42006206
PMCPMC13091437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.